The Vascular Biology and Hypertension Program focuses on molecular and cellular approaches to important problems in cardiovascular medicine. Active in clinical trials include novel therapeutic agents ...
Emerging research suggests reversible RNA editing mechanisms may influence heart disease biology while opening new avenues for biomarkers and next-generation cardiovascular therapies. Review: RNA ...
This Collection supports and amplifies research related to SDG 4: Learning & Education, SDG 5: Gender Equality and SDG 10: Reduced Inequalities. Cardiovascular diseases (CVDs) are the leading cause of ...
Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company advancing human cell innovation, announces the commercial ...
Cardiovascular disease is the leading cause of death in patients receiving hemodialysis, yet effective preventive therapies remain limited. Supplementation with n−3 polyunsaturated fatty acids, ...
Boston University Chobanian & Avedisian School of Medicine researchers Vanessa Xanthakis, PhD, FAHA, associate professor of ...
The Helmholtz Institute for Translational AngioCardioScience in Mannheim/Heidelberg has appointed vascular biologist Karina Yaniv from the Weizmann Institute as its new Scientific Director. Yaniv will ...
SCIENTISTS and public health experts are calling for a fundamental shift in how cardiovascular disease is diagnosed and treated, warning that current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results